Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat.
Sanofi Genzyme and Regeneron are committed to providing resources to advance research in dermatology in areas of unmet medical needs among patients with inadequately controlled moderate-to-severe atopic dermatitis.
Patient Video - Living with moderate-to-severe Atopic Dermatitis
Sanofi Genzyme Contacts
If you would like to get more information about moderate-to-severe Atopic Dermatitis or the use of Dupixent▼(dupilumab), please reach out to us!
We are also organising a promotional meeting to discuss the use of Dupixent in adults and adolescent (12 and older) with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. If you would like to be kept informed of the agenda and date, please consider reaching out to one of us.
We also have a range of resources available to you that you can find in the Sanofi Genzyme folder.